Chardan Capital: Maintains Ocugen (OCGN.US) rating, adjusted from buy to buy rating, and adjusted target price from $4.00 to $5.00.
Zhitong FinanceApr 22 19:50
Ocugen Analyst Ratings
BenzingaApr 22 19:44
Analysts Offer Insights on Healthcare Companies: Staar Surgical (STAA), Ocugen (OCGN) and Moderna (MRNA)
TipRanksApr 9 20:10
Ocugen Analyst Ratings
BenzingaApr 3 18:45
Buy Rating Affirmed for Ocugen on Strong Clinical Progress and Financial Stability
TipRanksApr 3 18:25
HC Wainwright & Co. Reiterates Buy on Ocugen, Maintains $7 Price Target
BenzingaFeb 22 19:46
Ocugen Analyst Ratings
BenzingaFeb 22 19:45
Buy Rating Affirmed for Ocugen on Strong Clinical Progress and Positive Financial Outlook
TipRanksFeb 22 19:20
HC Wainwright & Co. Maintains Buy on Ocugen, Raises Price Target to $7
BenzingaJan 24 19:18
Ocugen Analyst Ratings
BenzingaJan 24 19:17
Analyst Gives 'Buy' Rating to Ocugen Backed by Strong Financial Position and Promising Drug Pipeline
TipRanksNov 11, 2023 01:55
H.C. Wainwright Sticks to Their Buy Rating for Ocugen (OCGN)
TipRanksSep 14, 2023 22:05
Cantor Fitzgerald Maintains Overweight on Ocugen, Lowers Price Target to $2
BenzingaAug 31, 2023 22:19
Ocugen Analyst Ratings
BenzingaAug 31, 2023 22:18
Ocugen (OCGN) Gets a Buy From Noble Financial
TipRanksAug 23, 2023 20:05
Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS), LAVA Therapeutics (LVTX) and Ocugen (OCGN)
TipRanksAug 23, 2023 18:20
Ocugen Analyst Ratings
BenzingaAug 23, 2023 18:15
Ocugen (OCGN) Gets a Buy From Noble Financial
TipRanksMay 8, 2023 20:11
Chardan Research Raises Ocugen's Price Target to $4 From $3.50, Buy Rating Kept
MT NewswiresMay 8, 2023 19:11
Chardan Capital Maintains Buy on Ocugen, Raises Price Target to $4
BenzingaMay 8, 2023 16:35
No Data
No Data